Literature DB >> 8391018

Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]flumazenil.

J C Price1, H S Mayberg, R F Dannals, A A Wilson, H T Ravert, B Sadzot, Z Rattner, A Kimball, M A Feldman, J J Frost.   

Abstract

Kinetic methods were used to obtain regional estimates of benzodiazepine receptor concentration (Bmax) and equilibrium dissociation constant (Kd) from high and low specific activity (SA) [11C]flumazenil ([11C] Ro 15-1788) positron emission tomography studies of five normal volunteers. The high and low SA data were simultaneously fit to linear and nonlinear three-compartment models, respectively. An additional inhibition study (pretreatment with 0.15 mg/kg of flumazenil) was performed on one of the volunteers, which resulted in an average gray matter K1/k2 estimate of 0.68 +/- 0.08 ml/ml (linear three-compartment model, nine brain regions). The free fraction of flumazenil in plasma (f1) was determined for each study (high SA f1: 0.50 +/- 0.03; low SA f1: 0.48 +/- 0.05). The free fraction in brain (f2) was calculated using the inhibition K1/k2 ratio and each volunteer's mean f1 value (f2 across volunteers = 0.72 +/- 0.03 ml/ml). Three methods (Methods I-III) were examined. Method I determined five kinetic parameters simultaneously [K1, k2, k3 (= konf2Bmax), k4, and konf2/SA] with no priori constraints. An average kon value of 0.030 +/- 0.003 nM-1 min-1 was estimated for receptor-rich regions using Method I. In Methods II and III, the konf2/SA parameter was specifically constrained using the Method I value of kon and the volunteer's values of f2 and low SA (Ci/mumol). Four parameters were determined simultaneously using Method II. In Method III, K1/k2 was fixed to the inhibition value and only three parameters were estimated. Method I provided the most variable results and convergence problems for regions with low receptor binding. Method II provided results that were less variable but very similar to the Method I results, without convergence problems. However, the K1/k2 ratios obtained by Method II ranged from 1.07 in the occipital cortex to 0.61 in the thalamus. Fixing the K1/k2 ratio in Method III provided a method that was physiologically consistent with the fixed value of f2 and resulted in parameters with considerably lower variability. The average Bmax values obtained using Method III were 100 +/- 25 nM in the occipital cortex, 64 +/- 18 nM in the cerebellum, and 38 +/- 5.5 nM in the thalamus; the average Kd was 8.9 +/- 1.0 nM (five brain regions).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391018     DOI: 10.1038/jcbfm.1993.84

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  18 in total

1.  Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.

Authors:  Lia C Liefaard; Bart A Ploeger; Carla F M Molthoff; Ronald Boellaard; Adriaan A Lammertsma; Meindert Danhof; Rob A Voskuyl
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

2.  Patlak image estimation from dual time-point list-mode PET data.

Authors:  Wentao Zhu; Quanzheng Li; Bing Bai; Peter S Conti; Richard M Leahy
Journal:  IEEE Trans Med Imaging       Date:  2014-04       Impact factor: 10.048

3.  Three-dimensional visualization and quantification of the benzodiazepine receptor population within a living human brain using PET and MRI.

Authors:  S Pauli; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 4.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

5.  Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ).

Authors:  Charles M Laymon; Rajesh Narendran; Neale S Mason; Jonathan P Carney; Brian J Lopresti; Chester A Mathis; James M Mountz; Donald Sashin; W Gordan Frankle
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

6.  In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.

Authors:  W Gordon Frankle; Raymond Y Cho; Konasale M Prasad; N Scott Mason; Jennifer Paris; Michael L Himes; Christopher Walker; David A Lewis; Rajesh Narendran
Journal:  Am J Psychiatry       Date:  2015-07-02       Impact factor: 18.112

7.  Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.

Authors:  Ursula F Bailer; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Guido K Frank; Lisa Weissfeld; Claire W McConaha; Shannan E Henry; Sarah Brooks-Achenbach; Nicole C Barbarich; Walter H Kaye
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

8.  High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects.

Authors:  Sunil Sahdeo; Alexey Tomilov; Kelly Komachi; Christine Iwahashi; Sandipan Datta; Owen Hughes; Paul Hagerman; Gino Cortopassi
Journal:  Mitochondrion       Date:  2014-07-14       Impact factor: 4.160

9.  Carbon-11 and iodine-123 labelled iomazenil: a direct PET-SPET compari son.

Authors:  G Westera; A Buck; C Burger; K L Leenders; G K von Schulthess; A P Schubiger
Journal:  Eur J Nucl Med       Date:  1996-01

10.  Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects.

Authors:  W Gordon Frankle; Raymond Y Cho; Rajesh Narendran; N Scott Mason; Shivangi Vora; Maralee Litschge; Julie C Price; David A Lewis; Chester A Mathis
Journal:  Neuropsychopharmacology       Date:  2008-07-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.